Calneuron 1 anticorps (AA 51-150) (AbBy Fluor® 350)
-
- Antigène Voir toutes Calneuron 1 (CALN1) Anticorps
- Calneuron 1 (CALN1)
-
Épitope
- AA 51-150
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp Calneuron 1 est conjugé à/à la AbBy Fluor® 350
-
Application
- Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Homologie
- Human,Mouse,Rat,Dog,Cow,Pig,Horse,Chicken,Rabbit
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human Calneuron 1/CABP8
- Isotype
- IgG
- Top Product
- Discover our top product CALN1 Anticorps primaire
-
-
- Indications d'application
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- Calneuron 1 (CALN1)
- Autre désignation
- Calneuron 1/CABP8 (CALN1 Produits)
- Synonymes
- anticorps CALN1, anticorps CABP8, anticorps 9630012C17Rik, anticorps Cabp8, anticorps calneuron 1, anticorps CALN1, anticorps caln1, anticorps Caln1
- Sujet
-
Synonyms: CaBP8, CABP8_HUMAN, Calcium binding protein 8, Calcium binding protein, Calcium binding protein CABP8, Calcium-binding protein 8, Caln1, Calneuron I, Calneuron-1, Calneuron1.
Background: This gene encodes a protein with high similarity to the calcium-binding proteins of the calmodulin family. The encoded protein contains two EF-hand domains and potential calcium-binding sites. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2008].
-